The insurability of innovative pharmaceutical cancer technologies

The scientific literature, including several papers published in the IJHPR, has raised the issue of the spiraling cost of cancer treatment, including that of cancer drugs and other technologies such as gene and cell therapies. In this perspective, we review three criteria for insurability and show t...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenberg, Shuli Brammli, Dotan, Einat, Arazi, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751103/
https://www.ncbi.nlm.nih.gov/pubmed/33342428
http://dx.doi.org/10.1186/s13584-020-00426-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751103/
https://www.ncbi.nlm.nih.gov/pubmed/33342428
http://dx.doi.org/10.1186/s13584-020-00426-w

Ejemplares similares